# Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy

> **NCT01516866** · — · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 58 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **PROCEDURE:** Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging

## Key facts

- **NCT ID:** NCT01516866
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2015-09
- **Final completion:** 2018-01-01
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01516866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01516866, "Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01516866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*